In a nutshell This study aimed to investigate outcomes for patients with chronic-phase chronic myeloid leukemia who received nilotinib as a first-line treatment. This study concluded that nilotinib is a valuable treatment option for these patients. Some background Nilotinib (Tasigna) is a targeted therapy...
Read More
In a nutshell This study aimed to investigate the frequency of BCR-ABL kinase domain mutation detection and its prognostic significance in patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs). This study concluded that early mutation detection and use of 2nd and...
Read MoreIn a nutshell This study looked at the management of side effects of bosutinib (Bosulif) in the treatment of chronic myeloid leukemia. Researchers found that bosutinib was safe in the treatment of patients in whom other medications have failed. Some background Chronic myeloid leukemia is a cancer of the bone marrow. It can lead to an abnormal...
Read More
In a nutshell This study looked at the safety and effectiveness of switching from original brand imatinib (Gleevec) to generic imatinib in chronic myeloid leukemia (CML). The study found that switching from branded to generic imatinib is a safe option in these patients. Some background New medications on the market have a patent by their...
Read More
In a nutshell This study aimed to evaluate the effectiveness of nilotinib as a consolidation therapy for patients with chronic myeloid leukemia who had achieved a major response with imatinib. This study concluded that nilotinib led to safer, deeper responses in these patients. Some background Imatinib (Gleevec) is a tyrosine kinase inhibition (TKI)...
Read More
In a nutshell This study aimed to assess if a response to treatment within 12 months was linked with an improved quality of life in patients with chronic myeloid leukemia. Researchers concluded that achieving the best treatment response within 12 months was associated with better quality of life in these patients. Some background Chronic myeloid...
Read MoreIn a nutshell This study aimed to investigate the effectiveness and safety of a lower dose of dasatinib in chronic phase chronic myeloid leukemia patients. This study concluded that the lower dose of dasatinib was as effective and safer than the standard dose in these patients. Some background Dasatinib (Sprycel) is a tyrosine kinase inhibitor...
Read More
In a nutshell This study aimed to investigate the effectiveness and safety of bosutinib as a second line therapy for patients with chronic phase chronic myeloid leukemia (CML). This study concluded that bosutinib was effective and safe for these patients as a second line therapy. Some background Bosutinib (bosulif) is a tyrosine kinase inhibitor (TKI...
Read More
In a nutshell This study aimed to define the conditions necessary for stopping tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia. This study concluded that patients who maintain a deep molecular response have good molecular relapse-free survival and can be considered for treatment discontinuation. Some...
Read More
In a nutshell This study aimed to investigate the effectiveness and safety of ponatinib (Iclusig) for patients with chronic phase chronic myelogenous leukemia. This study concluded that ponatinib is safe and effective in this group of patients. Some background The Philadelphia chromosome (BCR-ABL1) is found in almost all patients with chronic...
Read More
In a nutshell This study compared side effects between two similar therapies – nilotinib (Tasigna) and dasatinib (Sprycel) – for chronic myeloid leukemia (CML). Researchers reported more serious side effects with dasatinib than with nilotinib. Some background Tyrosine kinase inhibitor (TKI) therapy is a standard first-line treatment...
Read More
In a nutshell This phase 1 and 2 trial aims to determine the effectiveness and optimal dose of Axitinib and Bosutinib in patients with chronic myeloid leukemia. The outcome to be measured is the response to treatment based on genetic analysis and blood cell count, and the side effects. The study is located in Houston, Texas, United States. The...
Read More
